KRIBIOLISA™ Elotuzumab (EMPLICITI™) ELISA

REF : KBI1292

Ver 2.0

RUO

Enzyme Immunoassay for the Quantitative Determination of Elotuzumab in human serum and plasma

RUO	For Research Use Only	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biologi isk
	Expiry D		Consu rating Instructions

For Research Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.

REF KBI1292 Σ 96 tests

KRISHGEN BioSystems| For US / Europe: toll free +1(888)-970-0827 tel: +1(562)-568-5005
For Asia / India: tel: +91(22)-49198700
Email: sales@krishgen.com

Introduction:


Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

Intended Use:

The KRIBIOLISA™ Elotuzumab (EMPLICITI™) ELISA is a rapid and easy method for the quantitative determination of Elotuzumab in human serum and plasma.

Principle:

The method employs indirect sandwich ELISA technique. SLAMF7 protein is pre-coated onto microwells. Samples and standards are pipetted into microwells and Elotuzumab present in the sample/standard are bound by the protein. After incubation the wells are washed and followed by addition of Anti-Human IgG:HRP conjugate into each well and incubated to form a complex. After washing microwells in order to remove any non-specific binding, the substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Elotuzumab present in the sample/standard. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.



Materials Provided:

Part	Description	Qty
SLAMF7 protein coated microtiter plate	96 well polystyrene microplate (12 strips of 8 wells) coated with SLAMF7 protein.	1 x 96 wells
Elotuzumab Standard	Recombinant Elotuzumab biosimilar in a buffered protein base with preservative sodium azide (lyophilized, concentration 1 ug/ml)	2 vials
Anti-Human IgG:HRP Conjugate	Anti-Human IgG conjugated to Horseradish Peroxidase with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
(1X) Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	2 x 50 ml
(1X) Standard Diluent	Buffered protein base with 1:1000 dilution human serum and preservative sodium azide < 0.01%	10 ml
(20X) Wash Buffer	20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	Stabilized Chromogen	12 ml
Stop Solution	0.73M Phosphoric Acid	12 ml
Instruction Manual		1 no

Materials to be provided by the End-User:

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25 ul to 1000 ul
3. Deionized (DI) water
4. Wash bottle or automated microplate washer
5. Graph paper or software for data analysis
6. Timer
7. Absorbent Paper

Handling/Storage:

1. All reagents should be stored at 2ºC to 8ºC for stability.
2. All the reagents and wash solutions should be used within 12 months from manufacturing date.
3. Before using, bring all components to room temperature (18-25ºC). Upon assay completion ensure all components of the kit are returned to appropriate storage conditions.
4. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
2. For Research Use Only.



Sample Preparation and Storage:

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at - 20°C.

Preparation Before Use:

Test sample preparation- Samples have to be diluted 1 in 1000 (v/v), e.g. 1 ul sample in 999 ul sample diluent, prior to assay. The samples may be kept at 2 - 8 °C for up to three days. Long-term storage requires - 20°C.

Reagent Preparation (all reagents should be diluted immediately prior to use):

1. Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
2. Bring all reagents to Room temperature before use.
3. To make Wash Buffer (1X); dilute 25 ml of 20X Wash Buffer in 475 ml of DI water.
4. **Standards Preparation**: Reconstitute the concentrated Standard lyophilized vial with 1 ml of Standard Diluent (1X) to obtain a concentration of 1 ug/ml. Keep the vial for 15 mins with gentle agitation before making further dilutions. Dilute 640 ul of reconstituted **Standard (1 ug/ml)** with 360 ul of Standard Diluent (1X) to generate a **640 ng/ml Standard Solution**. Prepare further **Standards** by serially diluting the Standard Solution as per the below table. Use the Standard Diluent (1X) as the Zero Standard (Standard No.0).

Standard Concentration	Standard Vial	Dilution Particulars
1 ug/ml	Lyophilized Standard	Lyophilized Standard provided in the Kit + 1ml of Standard Diluent (1X)
640 ng/ml	Standard No.7	640 ul Reconstituted Standard (1ug/ml) + 360 ul Standard Diluent (1X)
320 ng/ml	Standard No.6	500 ul Standard No.7 + 500 ul Standard Diluent (1X)
160 ng/ml	Standard No.5	500 ul Standard No.6 + 500 ul Standard Diluent (1X)
80 ng/ml	Standard No.4	500 ul Standard No.5 + 500 ul Standard Diluent (1X)
40 ng/ml	Standard No.3	500 ul Standard No.4 + 500 ul Standard Diluent (1X)

Use the	20 ng/ml	Standard No.2	500 ul Standard No.3 + 500 ul Standard Diluent (1X)
	10 ng/ml	Standard No.1	500 ul Standard No.2 + 500 ul Standard Diluent (1X)
	0 ng/ml	Standard No.0	Only Standard Diluent (1X)

Standards immediately upon reconstitution. Discard balance standard after use. Do not store them for further experiments.

.

Procedural Notes:

1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
2. Avoid assay of Samples containing sodium azide (NaN_3), as it could destroy the HRP activity resulting in under-estimation of the amount of Elotuzumab.
3. It is recommended that all Standards and Samples be assayed in duplicates.
4. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.
5. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromisation of the sensitivity of the assay.
6. The plates should be read within 30 minutes after adding the Stop Solution.
7. Make a work list in order to identify the location of Standards and Samples.

Assay Procedure:

1. It is strongly recommended that all Standards and Samples be run in duplicates or triplicates. A standard curve is required for each assay. All steps must be performed at 37°C

2. Pipette **100 ul** of prepared **Standards** or diluted **Samples** into the respective wells.

3. Cover the plate and incubate for 60 minutes at 37°C

4. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.

5. Add **100 ul** of **Anti-Human IgG:HRP conjugate** into each well.

6. Cover the plate and incubate for 60 minutes at 37°C

7. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step.

8. Add **100 ul** of **TMB Substrate** in each well.

9. Incubate the plate at 37°C for 30 minutes in dark. DO NOT SHAKE or else it may result in higher backgrounds and worse precision. Positive wells should turn bluish in color.

10. Pipette out **100 ul** of **Stop Solution**. Wells should turn from blue to yellow in color.

11. Read the absorbance at 450 nm with a microplate reader.

Calculation of Results:

Determine the Mean Absorbance for each set of duplicate Standards and Samples. Using graph paper, plot the average value (absorbance 450nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine the unknown Elotuzumab concentrations, find the unknown's Mean Absorbance value on the Y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Elotuzumab Concentration. If samples were diluted, multiply by the appropriate dilution factor. Software


which is able to generate a cubic spline curve-fit or 4PL (2nd order) is best recommended for automated results.

Note:
It is recommended to repeat the assay at a different dilution factor in the following cases:
- If the sample absorbance value is below the first standard.
- If the absorbance value is equivalent or higher than the 640 ng/ml standard.

Typical Data

Standard Concentration (ng/ml)	Absorbance A	Absorbance B	Mean Absorbance	Interpolated Concentration	% Interpolated Concentration against Actual Concentration
0	0.123	0.121	0.122	--	--
10	0.253	0.252	0.252	9.7	97.4
20	0.395	0.417	0.406	20.5	102.5
40	0.667	0.666	0.667	39.8	99.5
80	1.125	1.122	1.124	81.0	101.3
160	1.645	1.711	1.678	155.8	97.4
320	2.338	2.285	2.312	329.9	103.1
640	2.751	2.697	2.724	629.3	98.3

Typical Graph



Abs = absorbance at 450nm

Quality Control:

Sensitivity:

Limit of Quantification: It is defined as the lowest concentration of an analyte that can be determined with an acceptable repeatability and the LOQ was found to be 5 ng/ml.

Limit Of Detection: It is defined as the lowest detectable concentration corresponding to a signal of Mean of '0' standard plus 2* SD.
10 replicates of '0' standards were evaluated and the LOD was 5 ng/ml.

Specificity:
The protein used in the kit is HEK293 expressed protein for SLAMF7 comprising 215 amino acids with a predicted molecular mass of 23.8 kDa. The calibrators / standards used are calibrated against commercially sourced (EMPLICITI™) and is a humanized recombinant Elotuzumab biosimilar.

Precision:
Precision is defined as the percent coefficient of variation (%CV) i.e. standard deviation divided by the mean and multiplied by 100. Assay precision was determined by both intra (n=5 assays) and inter assay (n=5 assays) reproducibility on two pools with low (10 ng/ml), medium (80 ng/ml) and high (640 ng/ml)

concentrations. While actual precision may vary from laboratory to laboratory and technician to technician, it is recommended that all operators achieve precision below these design goals before reporting results.

Pool	Intra Assay %CV	Inter Assay %CV
Low	<10%	<10%
Medium	<5%	<5%
High	<5%	<5%

Safety Precautions:

- **This kit is for research use only**. Follow the working instructions carefully.

- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
- Do not smoke, eat or drink while handling kit material
- Always use protective gloves
- Never pipette material by mouth
- Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.

References:

Development and validation of electrochemiluminescence assays to measure free and total sSLAMF7 in human serum in the absence and presence of elotuzumab
J Postelnek, RJ Neely, MD Robbins, CR Gleason… - The AAPS journal, 2016 - Springer

Toward further simplification of elotuzumab therapy by subcutaneous administration
Y Shimura, T Tsukamoto, J Yamaguchi… - International Journal of …, 2020 - Springer

Highly sensitive detection of antibody nonspecific interactions using flow cytometry
EK Makowski, L Wu, AA Desai, PM Tessier - MAbs, 2021 - Taylor & Francis

Elotuzumab enhances the Th2-mediated immune response of dendritic cell induced by immunomodulatory drugs (IMiDs)
Y Azuma, T Ito, M Inaba, K Imai, M Hotta, A Satake… - 2019 - ashpublications.org

Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone+/-Elotuzumab
A Forslund, H Tang, C Duan, M Popa-McKiver… - Blood, 2019 - Elsevier

Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
H Wang, H Shi, X He, A Liao - OncoTargets and therapy, 2021 - ncbi.nlm.nih.gov

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
F van Rhee, SM Szmania, M Dillon… - Molecular cancer …, 2009 - AACR

SCHEMATIC ASSAY PROCEDURE

1. Remove all components, 30 minutes before adding into the assay plate.


Components (2-8ºC) → 30 mins RT Before Use → 

→ Thaw at Room Temperature (18-24ºC) → USE NOW

2. Avoid repeated cool-thaw of the components as there will be a loss of activity and this can affect the results.

Kit Components → AVOID → COOL (2-8ºC) → THAW (22±4ºC) → THAW (22±4ºC) → COOL (2-8ºC) → AVOID → NO CHANGE IN RESULTS


3.  Pipette **100 ul** prepared **Standards** / diluted **Samples** into each well.

4. Cover plate  and incubate for 

at 37°C.

5.  Aspirate and wash wells 4 times with **Wash Buffer (1X).**


6.  Pipette **100 ul Anti-Human IgG:HRP conjugate** into each well.

7. Cover plate  and incubate for 

at 37°C.

8.  Aspirate and wash wells 4 times with **Wash Buffer (1X).**

9.  Pipette **100 ul TMB Substrate** into each well.

10. Cover plate  and incubate for 

at 37°C.



11. Pipette **100 ul Stop Solution** into each well.

12. Read absorbance at 450nm with a  microplate reader within  of stopping reaction.

Typical Example of a Work List

Well #	Contents	Absorbance at 450 nm	Mean Absorbance	ng/ml Elotuzumab equivalent
1A 2A	0 ng/ml 0 ng/ml			
1B 2B	10 ng/ml 10 ng/m			
1C 2C	20 ng/ml 20 ng/ml			
1D 2D	40 ng/ml 40 ng/ml			
1E 2E	80 ng/ml 80 ng/ml			
1F 2F	160 ng/ml 160 ng/ml			
1G 2G	320 ng/ml 320 ng/ml			
1H 2H	640 ng/ml 640 ng/ml			
3A 4A	Sample Sample			
3B 4B	Sample Sample			

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2023

THANK YOU FOR USING KRISHGEN PRODUCT!

KRISHGEN BIOSYSTEMS®, GENLISA®, DHARMAPLEX™, GENBULK™, GENLISA™, KRISHZYME®, KRISHGEN®, KRIBIOLISA®, KRISHPLEX®, TITANIUM®, QUALICHEK® registered trademarks of KRISHGEN BIOSYSTEMS. ©KRISHGEN BIOSYSTEMS. RIGHTS RESERVED.

KRISHGEN BIOSYSTEMS OUR REAGENTS | YOUR RESEARCH |

EMPLICITI™ is a trade mark of Bristol-Myers USA

	S MTP rotein Coated Microtiter Plate (12 x 8 wells)
	E STD ab Standard
	HRP CONJ **orseradish Peroxidase**
	1X STD DIL **Diluent**
	1X DIL SAMP DIL **iluent**
	20X WASH BUF **uffer**
	SUB TMB **te**
	SOLN STOP
	Consult Instructions for Use
	C REF umber FE
	Expiration Date
	Storage Temperature

SYMBOLS KEY

are

ALL

|

registered

Squibb.,